Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
At present, triple therapy are recommended by various guidelines for the treatment of
Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment
failure rates with one week first line clarithromycin based triple therapy necessitating
salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact
duration of bismuth based second line treatment is not determined. Therefore, the
investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple
regimen as a second-line therapy.